Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong

This study has been terminated.
(Interim analysis of efficacy trial showed no drug efficacy.)
Sponsor:
Collaborator:
Collaborative Study Group (CSG)
Information provided by (Responsible Party):
Keryx Biopharmaceuticals
ClinicalTrials.gov Identifier:
NCT00462202
First received: April 16, 2007
Last updated: November 29, 2012
Last verified: November 2012

April 16, 2007
November 29, 2012
April 2007
March 2008   (final data collection date for primary outcome measure)
Observed ACR level from the first visit to the end of study [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Open label safety extension to assess long-term exposure to sulodexide (KRX-101) in patients with albumin and protein in their urine.
Observed ACR level from the first visit to the end of study
Complete list of historical versions of study NCT00462202 on ClinicalTrials.gov Archive Site
Not Provided
Safety evaluations including review of adverse events and lab parameters from first visit to end of study
Not Provided
Not Provided
 
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
An Open Label Tolerability and Safety Study of KRX-101 (Sulodexide Gelcaps) for the Treatment of Type 2 Diabetic Nephropathic Patients With Persistent Microalbuminuria in Australia, New Zealand, and Hong Kong

The purpose of this study is to assess the tolerability and safety of KRX-101 in treating persistent microalbuminuria in type 2 diabetic patients who are also being treated with stable, maximum tolerated doses of either ACE inhibitors or A2 receptor blockers.

Diabetes is one of the most common causes of end-stage renal disease (ESRD) in the U.S. and in many other developed nations. Despite advances in clinical care, including improvements in glycemic and blood pressure control, the number of new cases of diabetes-related ESRD continues to rise, especially in patients with type 2 diabetes.

The current standard of care for the prevention and treatment of diabetic renal disease includes screening all diabetic patients for microalbuminuria. Patients who test positive for microalbuminuria are then treated with either ACE inhibitors or A2 receptor blockers. Both of these classes of medication have been shown to reduce levels of microalbuminuria in some patient populations. This improvement in microalbuminuria has also shown a delay of progression to a number of other renal function problems, as well as a minimal delay in certain clinical events including ESRD.

Unfortunately, some patients achieve the majority of their therapeutic effect of ACE inhibitors or A2 receptor blockers within the first 6 months of therapy, and many of these patients continue to show persistent microalbuminuria. Therefore, these patients are at an increased risk of progressing to ESRD due to the lack of adequate benefit from their current medication.

Microalbuminuria has a straight-line relationship with adverse renal outcomes; therefore any level of reduction may have clinical benefit. It is reasonable to believe that patients who can reduce or have a complete remission of their microalbuminuria may also lessen the risk of progressing to ESRD. Thus, if KRX-101 is able to cause a reduction or complete remission of microalbuminuria to normoalbuminuria, patients may receive a significant clinical benefit.

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetic Nephropathy
  • Drug: sulodexide
    N/A
    Other Name: KRX-101
  • Drug: Sulodexide
    N/A
    Other Name: KRX-101
Experimental: Sulodexide
Open label extension to original trial
Interventions:
  • Drug: sulodexide
  • Drug: Sulodexide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
200
March 2008
March 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • At least 18 years of age and has successfully completed Keryx Study 101-301.
  • Diagnosis of DM2 based on ADA criteria.
  • Continued stable seated systolic blood pressure < 150 mmHg and diastolic blood pressure < 90 mmHg.
  • Provide written informed consent to participate in the study.
  • If female and of childbearing potential, must continue to be willing to use adequate contraception, as determined by the investigator, for the duration of the study.

Exclusion Criteria:

  • Evidence of hepatic dysfunction including total bilirubin > 2.0 mg/dL (34 micromol/L) or liver enzymes > 3 times upper limit of normal.
  • Unstable angina pectoris or New York Heart Association Class III or IV congestive heart failure.
  • A history of any major medical condition, including but not limited to: aortic aneurysm; myocardial infarction, stroke, or other cardiovascular events in the past 3 months; gastrointestinal bleeding in the past 3 months; HIV; and other medical conditions deemed serious by the investigator. Active Hepatitis B or C (currently active disease defined as an abnormal liver biopsy or persistent, elevated transaminases, SGOT, SGPT).
  • Any risk of bleeding, including a history of bleeding diathesis and a platelet count < 100,000/mm³.
  • Active or metastatic cancer (note: superficial basal carcinoma of the skin is not an exclusion).
  • Anticipated surgery within trial period.
  • History of noncompliance to medical regimens in Keryx Study No.101-301.
  • Participation in any experimental drug study in the past 60 days, except for KRX-101-301, prior to entry into the study, or plan to participate in any experimental drug study during the study period.
  • Lactation, pregnancy, or an anticipated or planned pregnancy during the study period.
  • Known allergy or intolerance to any heparin-like compounds.
  • Patients with other specific renal diseases known to be the cause of nephropathy, and patients with other specific, clinically significant renal disease.
  • Inability to give an informed consent or cooperate with the study personnel.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT00462202
KRX 101-302
Yes
Keryx Biopharmaceuticals
Keryx Biopharmaceuticals
Collaborative Study Group (CSG)
Study Director: Robert Atkins, MD Monash Medical Centre
Principal Investigator: Anne Reutens, MD Monash Medical Center
Keryx Biopharmaceuticals
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP